March 2025 – A landmark study validating the Analytics for Life (A4L) non-invasive coronary artery disease (CAD) detection system for mainland Chinese populations was published in Discover Medicine by Professor Qian Juying’s team at Zhongshan Hospital, Fudan University. As the core clinical research partner for this Sino-US collaborative project, CCRC Medtech provided pivotal support in cross-population efficacy validation through its end-to-end clinical capabilities and medical-engineering integration expertise.
625-Patient Single-Center Study Demonstrates Clinical Research Excellence
CCRC Medtech executed this prospective, single-center study at Zhongshan Hospital with 625 enrolled subjects, ensuring scientific rigor through:
-
Strict adherence to U.S. study inclusion/exclusion criteria for cross-population data comparability
-
Precision screening of signal quality/outliers, yielding 458 valid samples (including 348 significant CAD patients)
-
Bias-free analysis pairing A4L results with invasive coronary angiography (ICA), safeguarding conclusions
Benchmarking Medical-Engineering Collaboration
CCRC Medtech’s leadership in medical device translation stems from its multidisciplinary synergy and globally recognized study experience, including:
Cardiovascular Interventions
-
Hanchor Valve System (aortic regurgitation): Supported this domestically innovated device’s 13-center China study (128 high-risk AR patients), published in JACC: Cardiovascular Interventions (IF:11.7).
-
OPTION Trial (PI: Academician Ge Junbo): Co-executed this first global RCT (103 centers, 4,551 PCI patients) comparing indobufen+clopidogrel vs. aspirin+clopidogrel, published in Circulation (IF:38.6).
-
TARGET 3C Study: Validated OCT-guided vs. IVUS/QCA-guided coronary calcification therapy at EuroPCR 2024.
Neurointerventions
-
DIRECT-MT Trial (PI: Prof. Liu Jianmin): Global first RCT (41 centers, 656 stroke patients) proving direct thrombectomy’s non-inferiority to bridging therapy, published in NEJM (IF:96.2).
-
MAGIC-MT Trial: Coordinated this world’s largest RCT (722 subdural hematoma patients) on middle meningeal artery embolization (MMAE), published in NEJM.
-
PROTECH-MT Trial: Spearheaded the first RCT on flow-control-free thrombectomy (shorter procedure time/lower mortality), published in The Lancet (IF:88.5).
Cross-Domain Innovations
-
Contributed to ENCHANTED-2/MT, GRAND, and 170+ studies across 1,300+ centers.
-
Enabled 30+ China-developed devices’ global entry, including 3 FDA Breakthrough Designations.
“True medtech innovation must be rooted in clinical needs,” emphasizes CCRC Medtech. “We bridge lab breakthroughs to real-world impact by anchoring science to patient-centric execution.”
Looking Ahead: CCRC Medtech will continue advancing “medical-engineering integration”—propelling Chinese innovations globally while adapting global solutions for local needs—to build a more equitable healthcare future.
